Trials / Completed
CompletedNCT00847860
Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Matter Lesions
Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 200 (actual)
- Sponsor
- Peking University First Hospital · Academic / Other
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy of PDE-3 inhibitor, cilostazol, in prevention and treatment of vascular dementia, in those with brain white matter lesions and vascular risk factors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cilostazol | Cilostazol 100 mg bid for 12 months |
| DRUG | Aspirin | Aspirin 100 mg qd for 12 months |
Timeline
- Start date
- 2008-03-01
- Primary completion
- 2011-05-01
- Completion
- 2011-06-01
- First posted
- 2009-02-19
- Last updated
- 2015-05-06
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT00847860. Inclusion in this directory is not an endorsement.